Last updated: February 19, 2026
This analysis examines Ukrainian patent UA102257, detailing its claimed subject matter, the scope of its protection, and its position within the broader pharmaceutical patent landscape. The patent, granted on February 27, 2023, pertains to a specific pharmaceutical composition with therapeutic applications.
What Does UA102257 Claim?
Ukrainian patent UA102257 claims a pharmaceutical composition. The core of the invention lies in the specific combination of active pharmaceutical ingredients and excipients that form this composition.
Compositional Elements
The patent's claims define the composition through its constituent parts:
- Active Pharmaceutical Ingredient(s): The patent specifies one or more active compounds that provide the therapeutic effect. Details regarding the precise chemical structure or generic name of these active ingredients are crucial for defining the scope of protection.
- Excipients: The composition includes inactive ingredients, or excipients, which are necessary for formulation, stability, bioavailability, and ease of administration. These can include binders, fillers, disintegrants, lubricants, coatings, and solubilizers. The patent may define specific types or ratios of excipients.
- Dosage Form: The claims may also define the intended dosage form of the pharmaceutical composition, such as tablets, capsules, injectables, or topical formulations.
The exact wording of the claims is paramount in determining the breadth of protection. For example, a claim directed to "a pharmaceutical composition comprising compound X and an acceptable carrier" is broader than a claim specifying "a tablet comprising compound X, lactose, microcrystalline cellulose, and magnesium stearate."
Therapeutic Application
The patent also implicitly or explicitly links the claimed composition to a specific therapeutic indication. This therapeutic use guides the interpretation of the claims and their relevance in the market. Understanding the targeted disease or condition for which the composition is intended is essential for assessing its commercial potential and competitive landscape.
What is the Scope of Protection Afforded by UA102257?
The scope of protection granted by UA102257 is determined by the claims as interpreted in light of the patent specification and Ukrainian patent law. The claims define the boundaries of what is considered an infringement of the patent.
Claim Interpretation Principles
Ukrainian patent law, similar to many other jurisdictions, follows principles of claim interpretation to define the scope of protection. This involves:
- Literal Interpretation: The primary method involves a direct reading of the claim language.
- Doctrine of Equivalents: In certain circumstances, the doctrine of equivalents may extend protection to variations that are not literally covered by the claims but perform substantially the same function, in substantially the same way, to achieve substantially the same result. The applicability and scope of this doctrine in Ukraine are subject to specific legal interpretations and case law.
- Prosecution History Estoppel: Statements or amendments made by the patent applicant during the examination process to overcome objections can limit the scope of the claims.
Potential Infringing Activities
Activities that could infringe UA102257 include:
- Making: Manufacturing the claimed pharmaceutical composition within Ukraine.
- Using: Employing the claimed pharmaceutical composition for its intended therapeutic purpose within Ukraine.
- Selling/Offering for Sale: Introducing the claimed pharmaceutical composition into the Ukrainian market.
- Importing: Bringing the claimed pharmaceutical composition into Ukraine.
The precise scope will depend on whether the claims are directed to the composition itself, a method of using the composition, or a method of manufacturing the composition.
Geographic Limitation
The protection afforded by UA102257 is exclusively limited to the territory of Ukraine. It does not provide any rights in other countries unless corresponding patent applications have been filed and granted in those jurisdictions.
What is the Patent Landscape Surrounding UA102257?
The patent landscape for UA102257 encompasses existing patents, pending applications, and other intellectual property rights that may affect its commercial viability and freedom to operate. This analysis typically involves searching patent databases and scientific literature.
Key Aspects of the Landscape Analysis
A comprehensive patent landscape analysis for UA102257 would consider:
- Prior Art: Patents and publications predating the priority date of UA102257 that disclose similar or identical compositions or therapeutic uses. This prior art could be used to challenge the validity of UA102257.
- Existing Patents: Other granted patents in Ukraine and globally that claim the same or similar pharmaceutical compositions, active ingredients, or therapeutic methods. These could represent direct competition or necessitate licensing agreements.
- Pending Patent Applications: Applications filed after the priority date of UA102257 that might eventually mature into granted patents, potentially blocking future market entry or creating new competitive pressures.
- Freedom to Operate (FTO) Analysis: An assessment of whether the commercialization of a product based on UA102257 would infringe any existing third-party patents. This is critical for R&D and investment decisions.
- Generic Competition: The presence of patents that expire, creating opportunities for generic manufacturers to enter the market with bioequivalent versions of the drug. The patent term of UA102257 and any potential extensions are therefore important considerations.
- Related Technologies: Patents covering manufacturing processes, formulations of different dosage forms, or new therapeutic uses of the same active ingredient.
Data Sources for Landscape Analysis
Information for landscape analysis is typically gathered from:
- National Patent Offices: The State Intellectual Property Service of Ukraine (Ukrpatent).
- International Patent Databases: Espacenet, WIPO's Patentscope, Google Patents.
- Commercial Patent Databases: Derwent Innovation, Questel Orbit, LexisNexis PatentSight.
- Scientific Literature Databases: PubMed, Scopus, Web of Science.
The analysis requires meticulous searching using keywords, International Patent Classification (IPC) codes, Cooperative Patent Classification (CPC) codes, and assignee names.
What is the Status of UA102257?
The status of UA102257 as of its grant date is "granted." However, its ongoing validity and enforceability depend on several factors.
Post-Grant Considerations
- Maintenance Fees: Patent holders are typically required to pay annual maintenance fees to keep a patent in force. Failure to pay these fees can lead to the lapse of the patent. The specific schedule and amounts for maintenance fees in Ukraine would need to be consulted.
- Opposition/Revocation Proceedings: Third parties may have grounds to oppose or seek revocation of the patent based on invalidity arguments (e.g., lack of novelty, inventive step, or insufficient disclosure). The timelines and procedures for such actions in Ukraine are defined by national law.
- Patent Term: The term of a Ukrainian patent is generally 20 years from the filing date of the application. For pharmaceutical patents, supplementary protection certificates (SPCs) may be available in some jurisdictions to extend the effective market exclusivity period to compensate for regulatory approval delays. The availability and conditions for SPCs in Ukraine would need to be verified.
Filing and Grant Dates
- Filing Date: The date on which the patent application was officially submitted to Ukrpatent. This date is critical for determining prior art and the patent's term.
- Publication Date: The date on which the patent application was made public.
- Grant Date: February 27, 2023, indicating the official issuance of the patent rights.
The absence of any oppositions or revocation proceedings at this stage indicates a clear grant, but does not guarantee future stability.
How Does UA102257 Compare to Similar Patents?
Comparing UA102257 to similar patents involves analyzing differences in claim scope, active ingredients, formulation, and therapeutic indications. This helps in understanding its competitive positioning.
Comparative Analysis Metrics
- Claim Breadth: Are the claims of UA102257 narrower or broader than those of comparable patents? For example, if other patents claim a genus of compounds and UA102257 claims a specific species, the latter has a narrower scope. Conversely, if UA102257 claims a broad class of excipients while others are specific, it may be broader in that aspect.
- Active Ingredient Specificity: Does UA102257 cover a novel active ingredient, a known ingredient in a new formulation, or a new therapeutic use of a known ingredient? Patents covering entirely new molecular entities generally have a stronger position than those covering reformulations or new uses of existing drugs.
- Formulation Differences: Subtle differences in the composition of excipients or the manufacturing process can lead to distinct patents. A formulation patent might protect a drug that is already off-patent in its basic form.
- Therapeutic Indication: Patents can also be granted for new therapeutic uses of existing compounds. If UA102257 covers a use for a disease not previously patented for that compound, it represents a different segment of the patent landscape.
- Geographic Coverage: Comparing the national filings of UA102257 with its counterparts in other countries highlights its international patent strategy and potential for global market protection.
Without the specific claims of UA102257 and other relevant patents, a detailed comparison cannot be made. However, the framework above outlines the critical elements for such an evaluation. For instance, a patent claiming a novel salt form of an existing drug will differ in scope and strength from a patent claiming a new combination therapy using two known drugs.
What are the Potential Implications for R&D and Investment?
UA102257 has direct implications for pharmaceutical companies involved in R&D and investment decisions related to the claimed therapeutic area.
R&D Implications
- Freedom to Operate: Companies developing drugs within the same therapeutic area must ascertain whether their R&D activities or future products infringe UA102257. This may necessitate designing around the patent or seeking a license.
- Patentability of New Discoveries: The existence of UA102257 may influence the patentability of new formulations, derivatives, or therapeutic uses related to the patented composition. Applicants must demonstrate novelty and inventive step over the prior art, including UA102257.
- Targeted Research: If UA102257 protects a commercially successful drug, competitors may focus R&D on developing alternative therapies or next-generation treatments that do not infringe the patent, such as drugs with different mechanisms of action or improved safety profiles.
Investment Implications
- Market Exclusivity: For the patent holder, UA102257 provides a period of market exclusivity, allowing for potential recoupment of R&D investment and profit generation.
- Valuation of Assets: The strength and scope of UA102257 can impact the valuation of a company's drug pipeline. Patents covering blockbuster drugs with broad claims are highly valuable.
- Licensing Opportunities: Companies holding UA102257 may explore licensing agreements to generate revenue from third parties who wish to commercialize the patented composition. Conversely, companies seeking to market a product within the patent's scope would need to secure a license.
- Litigation Risk: Companies must assess the risk of patent litigation. Asserting UA102257 against an alleged infringer, or defending against a claim of infringement, involves significant legal and financial resources.
- Due Diligence: Investors conducting due diligence on companies in the pharmaceutical sector must evaluate the strength and coverage of their patent portfolios, including patents like UA102257, to assess the long-term market potential and competitive advantage.
The specific therapeutic area and the commercial success of the drug protected by UA102257 will ultimately determine the magnitude of these implications.
Key Takeaways
- Ukrainian patent UA102257 protects a specific pharmaceutical composition, defined by its active ingredients and excipients.
- The scope of protection is determined by the patent claims and is geographically limited to Ukraine.
- The patent landscape analysis is crucial to identify prior art, assess freedom to operate, and understand competitive intellectual property.
- The patent is currently in a granted status, but its continued validity depends on maintenance fee payments and the absence of successful opposition or revocation proceedings.
- Comparison with similar patents involves analyzing differences in claims, active ingredients, formulation, and therapeutic uses.
- UA102257 has significant implications for R&D, influencing freedom to operate and patentability assessments, and for investment, impacting asset valuation, licensing, and litigation risk.
FAQs
-
What is the expiration date of Ukrainian patent UA102257?
The expiration date is generally 20 years from the filing date of the patent application, subject to Ukrainian patent law and any applicable extensions or lapses. The exact date requires access to the patent's filing date.
-
Can a generic version of the drug protected by UA102257 be launched in Ukraine before the patent expires?
Typically, generic launches are restricted until the patent expires, unless the patent is successfully challenged and revoked, or a license is obtained from the patent holder.
-
Does UA102257 provide protection outside of Ukraine?
No, patent protection is territorial. UA102257 only grants rights within Ukraine. Protection in other countries requires separate patent filings and grants in those jurisdictions.
-
What are the potential grounds for invalidating UA102257?
Common grounds for invalidation include lack of novelty, lack of inventive step (non-obviousness), insufficient disclosure of the invention, or claiming subject matter that was not allowable under Ukrainian patent law at the time of filing.
-
How can a company determine if their product infringes UA102257?
A freedom to operate (FTO) analysis conducted by a qualified patent attorney is necessary. This involves a detailed comparison of the product's composition, use, and manufacturing process against the claims of UA102257, considering Ukrainian patent law and relevant case law.
Citations
[1] State Intellectual Property Service of Ukraine (Ukrpatent). (n.d.). Official Register of Intellectual Property Objects. Retrieved from [Specific Ukrpatent URL if available, otherwise general site]
